Slide 1: Immutep Corporate Presentation
Immutep Corporate Presentation August 2026 (ASX:IMM, NASDAQ:IMMP) Unlocking the power of the immune system to fight cancer and autoimmune disease 1
Slide 2: Forward Looking Statements
Forward Looking Statements The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarificati
Slide 3: Immutep Highlights
Immutep Highlights A leader in LAG-3 Four clinical-stage assets designed to safely empower the immune system to fight cancer and autoimmune diseases through the MHC Class II & LAG-3 pathways, including first-in-class immunotherapy immunotherapies eftilagimod alfa (efti) and IMP761. Diversified oncol
Slide 4: Deep Clinical Pipeline in Oncology & Autoimmune Diseases
Deep Clinical Pipeline in Oncology & Autoimmune Diseases Indication – Trial Phase I Phase II Phase III Collaborations Commercial Rights ONCOLOGY Eftilagimod alfa (efti) Lung Cancer – TACTI-004 Efti + Pembrolizumab + Chemotherapy DISCONTINUED* MHC Class II agonist Lung / Head & Neck Cancers – TACTI-0
Slide 5: Oncology
Oncology Eftilagimod Alfa (Efti): Only immunotherapy in clinical development that activates antigen-presenting cells or APCs (e.g. dendritic cells, monocytes) directly via the MHC Class II pathway to fight cancer Efti: A soluble fusion protein with the four extracellular domains of LAG-3 fused to hu
Slide 6: Activating a Broad Anti-Cancer Immune Response with Efti
Activating a Broad Anti-Cancer Immune Response with Efti Immature Efti dendritic cell CD8+ CD4+ (iDC) T cells T cells IFN-γ CXCL10 Mature DC NK cells Monocytes Cancer Efti directly activates powerful immune cells called dendritic cells by binding to MHC Class II. This initiates a broad adaptive & in
Slide 7: Previous Data With Efti in Multiple Oncology Indications
CONFIDENTIAL Absolute Lymphocyte Count (ALC) Increase linked to improved OS Previous Data With Efti in Multiple Oncology Indications The addition of efti to chemotherapy and/or anti-PD-1 therapy has been observed to lead to an increase of lymphocyte counts in the peripheral blood in several cancer t
Slide 8: Efti’s Key Attributes
Efti’s Key Attributes Advantages of efti’s subcutaneous administration Key Attributes of Efti Immunotherapy • Generates systemic anti-cancer immune response • Better patient experience and access to treatment vs. ➢ Real innovation –> Efti is a first-in-class asset unlike any intravenous (IV) adminis
Slide 9: Strategic Collaboration and Licensing Agreement for Efti
CONFIDENTIAL Strategic Collaboration and Licensing Agreement for Efti Licensing Agreement with Dr. Reddy’s Immutep entered into a strategic collaboration & licensing agreement with Dr. Reddy’s in December 2025. Dr. Reddy’s holds exclusive rights to develop and commercialise efti in the licensed Larg
Slide 10: Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer Market Context Lung cancer is the leading cause of cancer death and non-small cell lung cancer (NSCLC) comprises 80 to 85% of all lung cancers1,2 ~2.0 million NSCLC diagnoses annually Total addressable NSCLC drug market expected to reach US$48 billion in 2031 with over 50%
Slide 11: TACTI-002/KEYNOTE-798: Strong Efficacy with Efti + KEYTRUDA
TACTI-002/KEYNOTE-798: Strong Efficacy with Efti + KEYTRUDA Benchmarking Efti + KEYTRUDA to KEYTRUDA Alone In collaboration with Objective Response Rate Progression Free Survival Overall Survival Results offer strong evidence of efti’s complementary effect with PD-1 inhibitors and its unique stimula
Slide 12: INSIGHT-003: Strong Efficacy from Efti + KEYTRUDA + Chemo
INSIGHT-003: Strong Efficacy from Efti + KEYTRUDA + Chemo Benchmarking Efti + KEYTRUDA + Chemo in non-squamous 1L NSCLC to KEYTRUDA + Chemo Overall Survival Objective Response Rate 35 75 75.0 Mature mOS of 30.9 months in the 30.9 70 68.0 overall population (N=51) and 30 65 62.1 30.9 months in patien
Slide 13: TACTI-004 Phase III trial discontinued following futility analysis
TACTI-004 Phase III trial discontinued following futility analysis Active, not recruiting Discontinued • TACTI-004/KEYNOTE-F91 Phase III trial evaluating efti + KEYTRUDA + chemotherapy in 1L NSCLC. • Conducted as a global randomized Phase III study in collaboration with Merck & Co. (MSD), demonstrat
Slide 14: TACTI-004: Efti's Typical Immune Activation Was Not Observed
TACTI-004: Efti's Typical Immune Activation Was Not Observed • Preliminary immune monitoring indicates that efti-treated patients in TACTI-004 exhibited a markedly different immune activation profile compared with previous studies, based on absolute lymphocyte counts (ALC) and circulating monocyte c
Slide 15: Head and Neck Cancer
Head and Neck Cancer Differentiated clinical and regulatory positioning underpin late-stage development Market Context Head and neck squamous cell carcinoma (HNSCC) encompasses a spectrum of heterogeneous diseases originating in the oral cavity, pharynx, and larynx More than 890,000 HNSCC diagnoses
Slide 16: 1L HNSCC CPS <1: Limited Competition and a Valuable Market
1L HNSCC CPS <1: Limited Competition and a Valuable Market 2027 2028 2029 Head & Neck Cancer $2.8 billion market1 1L HNSCC CPS <1 No Phase III trials targeting CPS<1 CPS 1-19 1L HNSCC CPS >20 CPS >1 CPS <1 1L HNSCC CPS >20 CPS <1 represents up to Limited competition in Standard-of-care therapies in
Slide 17: 1L HNSCC CPS <1: Strong Results from Efti + KEYTRUDA
1L HNSCC CPS <1: Strong Results from Efti + KEYTRUDA In collaboration with Overall 12-month Progression Objective Complete Safety: Grade >3 Survival (OS) OS Rate Free Survival Response Rate Responses Adverse Reactions Time (months) Percentage (%) Time (months) Percentage (%) Percentage (%) Percentag
Slide 18: Soft Tissue Sarcoma
Soft Tissue Sarcoma Differentiated clinical and regulatory positioning underpin late-stage development Market Context Soft tissue sarcomas are rare, heterogeneous malignancies with limited effective treatment options and high unmet medical need. Resectable cases represent ~60% of the STS market, val
Slide 19: STS: High Unmet Need and a Valuable Market
STS: High Unmet Need and a Valuable Market Soft Tissue Sarcoma Incidence per Annum1 ~1.1K 2027 2028 2029 ~16.7K (Japan) (EU4 + 1) No Active Phase III trials with Immunotherapy (IO)* ~13.9K / (North America) Resectable Current ~94.7K cases (rest of 16MM) STS Standard of Care ± Treatments3 Surgery Rad
Slide 20: STS: Strong Data May Continue with Improved Survival
STS: Strong Data May Continue with Improved Survival EFTISARC-NEO Phase II met primary endpoint. Oral presentations at ESMO 2025 & CTOS 2025. 51.5% tumour Tumour hyalinization/fibrosis associated with improved hyalinization/fibrosis survival.1 Upcoming survival-related endpoints may be over 3X highe
Slide 21: Trials Evaluating Efti in Early-Stage & Metastatic Breast Cancer
Trials Evaluating Efti in Early-Stage & Metastatic Breast Cancer Early-stage Breast Cancer Metastatic Breast Cancer George Washington (GW) Cancer Center initiating Phase AIPAC-003 Phase II is evaluating efti + chemo for II evaluating neoadjuvant efti as monotherapy and with metastatic HER2-neg/low b
Slide 22: Autoimmune Diseases
Autoimmune Diseases IMP761: First-in-class LAG-3 agonist antibody designed to selectively silence autoreactive LAG-3+ T cells, the root cause of many autoimmune disorders IMP761: A LAG-3 agonist antibody
Slide 23: Targeting Autoimmune Disease with Immune Checkpoint Agonists
Targeting Autoimmune Disease with Immune Checkpoint Agonists “These findings further support the potential clinical benefits of a LAG-3 agonist in the treatment of human autoimmunity”1 The Concept Present Approaches Target the Symptoms of Autoimmune Diseases • Acting downstream of disease pathology
Slide 24: Advantages of Targeting LAG-3 in Autoimmunity
Advantages of Targeting LAG-3 in Autoimmunity Selective expression and unique inhibitory pathway enable LAG-3 targeting in autoimmunity Targeted Approach LAG-3 is selectively expressed on activated T cells at sites of chronic inflammation, with low expression in peripheral tissues and blood Enables:
Slide 25: IMP761: First-in-Class LAG-3 Agonist a Potential Game-Changer
IMP761: First-in-Class LAG-3 Agonist a Potential Game-Changer IMP761 increases “brake” function of the LAG-3 immune checkpoint and its natural down-regulation of autoreactive memory IMP761 T cells, which represent the root cause of Suppress LAG-3 many disorders. LAG-3 proliferation, Antigen- activat
Slide 26: Clinical Development of IMP761
Clinical Development of IMP761 Delayed Type Hypersensitivity Model to Test T-cell Targeting Investigational Agents “The KLH neo-antigen challenge model provides a robust, standardized, and ethically sound way to elicit a controlled adaptive immune response in healthy volunteers. By combining systemi
Slide 27: Clinical Development of IMP761
Clinical Development of IMP761 Smart Phase I Design For Early Proof of Concept Key aspects: • Placebo-controlled, double-blind Phase I (~80 healthy volunteers) • Centre for Human Drug Research (CHDR, Leiden, NL) • Study completion Part B Q2 2026, Part C ongoing • Read-out: Safety, PK, Dose response
Slide 28: Positive Interim Phase I Data for IMP761 at EULAR 2026
Positive Interim Phase I Data for IMP761 at EULAR 2026 First-in-class LAG-3 agonist antibody shows significant pharmacodynamic activity Key Interim Phase I Results • Primary endpoint met: favourable safety and tolerability demonstrated in the single ascending dose part of the study • Statistically s
Slide 29: Summary
Summary • Immutep is a leader in immunotherapy with substantial opportunity in both oncology & autoimmune diseases First-in-class • Efti is the only immunotherapy that activates the immune system via the MHC Class assets in oncology II pathway and has significant potential to redefine cancer treatme
Slide 30: Thank You
Thank You . t ® Empowering the Immune System P